Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Recent Articles
28 Million Elective Surgeries Worldwide Estimated to be Delayed by COVID-19
A study published in the British Journal of Surgery estimates that 28.4 million elective surgeries worldwide could be canceled or postponed in 2020 because...
New Data on SARS-CoV-2-Reactive T Cells Provide Insights into Immunity
Two new studies found that patients with COVID-19, as well as some people who have not been infected with SARS-CoV-2, possess T-cells that target...
Omidubicel Shows Efficacy for Patients Requiring Transplant
A clinical safety and efficacy trial of omidubicel, an investigational cell therapy for patients in need of allogeneic hematopoietic cell transplantation, achieved its primary...
FDA Announces Plan to Relaunch Onsite Facility Inspections
The FDA has announced a partnership with the Centers for Disease Control and Prevention (CDC) to develop a plan for relaunching surveillance inspections. The...
Coagulation Dysregulation
Clinical knowledge about COVID-19-associated coagulopathy, including risk factors for development and how to prevent and manage hypercoagulability and thrombosis, continue to evolve as new...
Current Issue
May 2020, Volume 6, Issue 6
This issue discusses AI's potential to improve patient care, debates using donors with clonal hematopoiesis for alloHCT, and more.
